New Prostate Cancer Screening Tool Offers Earlier Detection Than Standard Methods

Health Points

• The Stockholm3 test detects aggressive prostate cancers earlier and more accurately than traditional PSA screening alone
• Researchers found the blood test reduced unnecessary biopsies by 51% while catching more dangerous cancers
• The test combines blood protein markers, genetic risk factors, and clinical data to assess cancer probability

A newly validated blood test shows promise for detecting aggressive prostate cancer earlier than conventional screening methods, according to research presented at the American Urological Association’s annual meeting. The Stockholm3 test could transform how physicians approach prostate cancer detection in men over 50.

The research examined data from more than 56,000 Swedish men aged 50 to 74 who underwent screening between 2018 and 2021. Scientists compared outcomes between men screened with the Stockholm3 test and those who received standard PSA (prostate-specific antigen) testing.

“What we found was that the Stockholm3 test was better at finding aggressive, clinically significant prostate cancer,” said Dr. Tobias Nordström, the study’s lead author and associate professor at Karolinska Institute in Sweden.

The Stockholm3 test works differently than traditional PSA screening. Instead of measuring only one protein marker in the blood, it analyzes multiple proteins associated with prostate cancer, incorporates genetic risk factors, and considers clinical information like age and family history to generate a personalized risk score.

Results showed the test identified 17% more aggressive cancers compared to PSA screening alone. These are the dangerous, fast-growing tumors that require prompt treatment rather than slow-growing cancers that may never cause health problems.

Perhaps equally important, the Stockholm3 test dramatically reduced unnecessary medical procedures. The study found it led to 51% fewer biopsies overall while still catching more of the cancers that matter most.

“We’re not just finding more cancer—we’re finding the right cancer,” Nordström explained. “And we’re sparing men from invasive procedures they don’t need.”

Prostate biopsies carry risks including bleeding, infection, and anxiety. Reducing unnecessary biopsies while improving cancer detection represents a significant advancement in men’s health care.

The research also revealed that men screened with Stockholm3 were 36% less likely to receive an overdiagnosis—meaning detection of slow-growing cancers that would never have caused symptoms or shortened life expectancy. Overdiagnosis has long been a concern with prostate cancer screening, as treatment can cause side effects including erectile dysfunction and urinary incontinence.

Prostate cancer remains the second most common cancer among American men after skin cancer. The American Cancer Society estimates approximately 299,010 new cases will be diagnosed in 2024, with about 35,250 deaths from the disease.

“Early detection is critical for prostate cancer outcomes,” said Dr. William Catalona, a prostate cancer expert at Northwestern University who was not involved in the study. “But we need to balance finding cancer early with avoiding unnecessary treatment of insignificant disease.”

The Stockholm3 test has been available in Europe since 2018 and recently received FDA clearance for use in the United States. However, it’s not yet widely available at American medical centers, and insurance coverage remains limited.

Men considering prostate cancer screening should discuss their individual risk factors with their physician. The U.S. Preventive Services Task Force recommends that men ages 55 to 69 make an individual decision about screening after talking with their doctor about the potential benefits and harms.

Risk factors for prostate cancer include age over 50, family history of the disease, and African American ethnicity. Men with a father or brother who had prostate cancer face more than double the average risk.

While the Stockholm3 test shows considerable promise, researchers emphasize that it represents one tool in the cancer detection toolkit rather than a complete solution. Men who receive elevated risk scores still require confirmation through biopsy before beginning treatment.

The Swedish research team continues following study participants to track long-term outcomes and cancer-related deaths. These extended results will help physicians better understand the test’s ability to identify cancers that truly threaten patients’ health and longevity.

“This is an important step forward in precision medicine for prostate cancer,” Nordström said. “We’re moving toward screening that’s tailored to each individual’s risk, rather than one-size-fits-all testing.”

For now, men concerned about prostate cancer should maintain regular checkups with their healthcare providers and discuss whether newer screening options like Stockholm3 might be appropriate for their situation. Traditional PSA testing remains the standard screening method at most American medical facilities, though that may change as evidence supporting more sophisticated approaches continues to accumulate.